Repatha vs Losartan: Cost, Access, and What Women Need to Know

What Are These Drugs and Why Are Women Comparing Them?

Repatha and losartan address two separate cardiometabolic risks: high LDL cholesterol and high blood pressure. Women are asking about them together because cardiovascular disease is the leading cause of death in women, and both drugs appear on cardiometabolic treatment plans. The honest answer to "is Repatha better than losartan" is that you can rarely swap one for the other. They are not head-to-head competitors the way two statins might be.

Still, the comparison matters for practical reasons. A woman with newly recognized familial hypercholesterolemia who is also managing hypertension may be weighing which condition gets prioritized when her insurance is fighting back. A postmenopausal woman with established atherosclerotic cardiovascular disease (ASCVD) may need both, but affordability constrains the conversation. This article gives you the numbers and the clinical context to have that conversation well.

How Repatha Works

Evolocumab (brand name Repatha) is a fully human monoclonal antibody that blocks PCSK9, a protein that degrades LDL receptors on liver cells. By neutralizing PCSK9, evolocumab allows more LDL receptors to survive and pull LDL particles out of circulation. In the FOURIER trial, evolocumab reduced LDL by approximately 59% from baseline on top of statin therapy, translating to a 15% relative risk reduction in the composite of major adverse cardiovascular events (MACE) over a median of 2.2 years in adults with established ASCVD.

How Losartan Works

Losartan is an angiotensin II receptor blocker (ARB). It blocks the AT1 receptor, which reduces vasoconstriction and aldosterone secretion, lowering blood pressure and reducing cardiac afterload. The LIFE trial compared losartan to atenolol in 9,193 patients with hypertension and left ventricular hypertrophy. Losartan produced a 13% reduction in the composite primary endpoint of cardiovascular death, stroke, and myocardial infarction versus atenolol, driven largely by a striking 25% stroke reduction, despite similar blood pressure lowering between the two arms.

Cost and Access: The Starkest Difference Between These Two Drugs

Cost is where the comparison becomes most practically significant for women making real-world decisions.

Repatha's Price Barrier

Repatha's list price in the United States runs approximately $650, $700 per month for the standard 140 mg every-two-weeks or 420 mg monthly dosing. Without insurance or manufacturer assistance, annual costs exceed $7,500. The FDA approved evolocumab in August 2015 and it remains brand-only; no biosimilar has reached widespread U.S. Market penetration at price parity. Amgen offers a patient assistance program (Repatha SupportPlus) that can reduce or eliminate cost for qualifying patients, but navigating prior authorization, step-therapy requirements, and income verification is a real administrative burden.

Commercial insurance typically requires documented failure or intolerance of maximally tolerated statin therapy before approving a PCSK9 inhibitor. Medicare Part D covers Repatha but often in a specialty tier with significant cost-sharing before the catastrophic threshold.

Losartan's Affordability

Generic losartan is one of the most affordable prescription drugs in the U.S. Pharmacy market. At major discount programs such as GoodRx, a 30-day supply of losartan 50 mg can cost as little as $4, $10. It requires no prior authorization at most insurers and is available on nearly every formulary, including Medicaid. The original patent expired in 2010, and the generic market is mature and stable.

A Practical Cost Comparison Table

| Factor | Repatha (evolocumab) | Losartan (generic) | |---|---|---| | Monthly list price | $650, $700+ | $4, $15 | | Generic available | No (brand only) | Yes | | Prior authorization required | Almost always | Rarely | | Manufacturer assistance | Yes (SupportPlus) | Not needed | | Delivery route | Subcutaneous injection | Oral tablet | | Dosing frequency | Every 2 weeks or monthly | Once daily |

Trial Evidence: What the Data Actually Shows

No randomized controlled trial has directly compared evolocumab against losartan. The research brief for this article confirms that, and it would be misleading to present the two as competing within the same outcome framework. What we have are two separate high-quality trials in different patient populations, with different endpoints.

FOURIER: Evolocumab in Established ASCVD

FOURIER enrolled 27,564 adults with established atherosclerotic cardiovascular disease, all on optimized statin therapy, and randomized them to evolocumab or placebo. The primary composite endpoint was cardiovascular death, MI, stroke, unstable angina requiring hospitalization, or coronary revascularization.

Key results:

• LDL lowered from a median of 92 mg/dL to 30 mg/dL in the evolocumab arm
• 15% relative risk reduction in primary MACE endpoint (HR 0.85; 95% CI 0.79 to 0.92)
• 20% relative risk reduction in the key secondary endpoint of cardiovascular death, MI, or stroke
• No significant difference in all-cause mortality over the 2.2-year median follow-up

Women represented only about 25% of FOURIER participants. Data from the FOURIER sex-stratified analysis showed directionally consistent benefit in women, but the trial was not powered to detect statistically significant differences by sex. This is a genuine evidence gap, and any clinician who presents PCSK9 inhibitor benefit in women with the same confidence as in men is overstating the data.

LIFE: Losartan in Hypertension With LVH

The LIFE trial enrolled adults aged 55 to 80 with hypertension and electrocardiographic left ventricular hypertrophy (LVH), randomized to losartan-based or atenolol-based regimens. Women made up 54% of enrolled participants, which is notably more representative than many cardiovascular outcome trials.

Key results:

• 13% relative risk reduction in the composite primary endpoint (fatal/nonfatal stroke, MI, or cardiovascular death)
• 25% relative risk reduction specifically in stroke (p = 0.001)
• New-onset diabetes was reduced 25% in the losartan arm versus atenolol, a finding particularly relevant to women with metabolic risk factors

The stroke-protective effect of losartan in LIFE is one of the reasons ARBs carry a class preference in patients with hypertension and LVH in major guidelines, including AHA/ACC hypertension guidelines.

Women-Specific Physiology: How Sex Hormones Change the Picture

Cardiovascular risk in women tracks differently across the reproductive lifespan than it does in men, and this shapes how each drug fits into a woman's care plan.

Reproductive Years (Ages 20 to 45)

Estrogen exerts a broadly cardioprotective effect during reproductive years, suppressing PCSK9 expression. Research published in Arteriosclerosis, Thrombosis, and Vascular Biology found that circulating PCSK9 levels are lower in premenopausal women than in men of similar age, and rise after menopause. This means premenopausal women with familial hypercholesterolemia may present with somewhat lower LDL than their male counterparts but should not have risk minimized based on sex alone.

Blood pressure in reproductive-age women is generally lower than in men. Hypertension in this age group often has a specific driver: oral contraceptives increase renin substrate and can raise blood pressure in susceptible women. Losartan may be considered in OCP-related hypertension, though stopping the offending contraceptive is the preferred first step.

Perimenopause (Typically Ages 45 to 55)

The perimenopausal transition brings a well-documented rise in LDL cholesterol, often 10 to 20 mg/dL, independent of dietary or weight changes. This is driven by falling estrogen, which normally upregulates hepatic LDL receptor expression. Simultaneously, blood pressure tends to rise, partly due to increasing sympathetic tone and renin-angiotensin-aldosterone system activation. A woman entering perimenopause may find herself suddenly needing attention to both lipids and blood pressure, which is when Repatha and losartan may appear on the same prescription pad.

Postmenopause

Postmenopausal women carry cardiovascular risk that approaches or exceeds age-matched men by their seventh decade. LDL levels are frequently highest in the decade after menopause. Established ASCVD is the setting where PCSK9 inhibitors like Repatha carry their strongest evidence base. For postmenopausal women with hypertension, losartan's renal-protective properties (via AT1 blockade reducing glomerular hyperfiltration) are additionally relevant, particularly in women with diabetic nephropathy or chronic kidney disease.

PCOS

Women with polycystic ovary syndrome carry a substantially elevated cardiometabolic burden, including dyslipidemia, insulin resistance, and hypertension, often appearing in the mid-30s. PCOS is associated with adverse lipid profiles including elevated LDL and triglycerides. Both drugs may eventually appear in a PCOS management plan, though neither is PCOS-specific in its indication.

Pregnancy and Lactation: Both Drugs Are Contraindicated

This is a required section for any drug comparison on WomanRx, and the news here is unambiguous for both agents.

Repatha (Evolocumab) in Pregnancy and Lactation

Evolocumab is classified as contraindicated in pregnancy by the FDA. Animal studies showed fetal developmental toxicity. Human data are limited because trials excluded pregnant women, but the mechanism (suppression of PCSK9 during fetal lipid metabolism development) raises concern. Cholesterol is necessary for normal fetal neurological and cell membrane development; dramatically reducing maternal LDL during organogenesis carries theoretical risk.

Women of reproductive age prescribed Repatha should use effective contraception during treatment. If you become pregnant while on evolocumab, stop the drug immediately and contact your prescribing clinician. It is not known whether evolocumab transfers into human breast milk in clinically significant amounts, but given the uncertainty and the baby's potential exposure, use during lactation is not recommended.

Losartan in Pregnancy and Lactation

Losartan carries an FDA black-box warning for use in pregnancy. It is teratogenic in the second and third trimesters, causing fetal renal dysplasia, oligohydramnios, pulmonary hypoplasia, and neonatal death. This is a class effect of all ARBs (and ACE inhibitors). If you discover you are pregnant while taking losartan, stop the medication the same day and call your OB or prescriber.

Losartan is also not recommended during breastfeeding. It is detected in animal milk, and no adequate human lactation data exist. For postpartum hypertension, nifedipine or labetalol are better-studied, preferred options during lactation per ACOG guidance on postpartum hypertension.

Women of childbearing age taking losartan for hypertension should use reliable contraception and have a clear plan for switching to a pregnancy-safe antihypertensive (such as labetalol, nifedipine extended-release, or methyldopa) the moment they decide to try to conceive.

Who This Is Right For (and Who It Is Not)

Repatha May Be Right For You If:

• You have established ASCVD (prior MI, stroke, or peripheral arterial disease) and your LDL remains above 70 mg/dL on maximally tolerated statin therapy
• You have familial hypercholesterolemia (heterozygous or homozygous) and cannot reach LDL targets with statins alone
• You are statin-intolerant and have high ASCVD risk requiring LDL reduction
• You are postmenopausal with very high cardiovascular risk and your lipid goals are not being met
• You can manage prior authorization or qualify for Amgen's patient assistance program

Repatha Is Less Appropriate If:

• You are pregnant, planning pregnancy, or breastfeeding (contraindicated)
• You have high LDL but low 10-year ASCVD risk and have not yet tried statin therapy
• Cost or injection-site tolerance is a barrier you cannot overcome
• Your primary cardiometabolic problem is blood pressure, not cholesterol

Losartan May Be Right For You If:

• You have hypertension requiring medical treatment, especially with LVH, diabetic nephropathy, or CKD
• You have had ACE-inhibitor-induced cough (losartan does not cause this class effect)
• You are postmenopausal with hypertension and metabolic risk
• You have PCOS with elevated blood pressure

Losartan Is Not Appropriate If:

• You are pregnant or trying to conceive (black-box teratogen)
• You have hyperkalemia or significant renal artery stenosis
• You are breastfeeding (switch to a safer agent)
• Your primary problem is high cholesterol without hypertension

Combining Repatha and Losartan

For a postmenopausal woman with both established ASCVD and hypertension, a cardiologist may prescribe both drugs. They have no significant pharmacokinetic interaction. Evolocumab is a biologic and is not metabolized through CYP450 pathways; losartan is metabolized by CYP2C9 to its active metabolite EXP3174. There is no shared metabolic pathway to create a drug-drug interaction.

The American College of Cardiology and AHA recommend managing LDL and blood pressure as separate, parallel treatment targets rather than prioritizing one over the other in high-risk patients. Women with both elevated LDL on statin therapy and uncontrolled hypertension benefit from treatment of both, and Repatha plus losartan can reasonably appear together on a polypharmacy list.

Getting Access to Repatha: What the Insurance Fight Looks Like

Women are disproportionately affected by delays in specialty drug access because of time costs associated with caregiving and more frequent out-of-pocket spending on health. Here is a practical roadmap:

Step 1: Document Statin Trials

Most insurers require evidence that you tried at least two statins at maximally tolerated doses, or have documented statin intolerance. Keep records of each statin, dose, duration, and reason for discontinuation.

Step 2: Get an LDL Below Target Documented

Your clinician will need a recent lipid panel showing LDL above the guideline threshold despite statin therapy. For established ASCVD, the AHA/ACC threshold for PCSK9 inhibitor consideration is LDL >70 mg/dL on maximally tolerated statin.

Step 3: Apply for Amgen SupportPlus Early

Even if insurance eventually approves Repatha, starting the manufacturer assistance application early protects you from gaps in coverage during the prior authorization process. Amgen's program can reduce or eliminate cost-sharing for commercially insured patients and provide free drug for uninsured or underinsured patients who meet income criteria.

Step 4: Consider Biosimilar Availability

As of early 2025, inclisiran (Leqvio), a twice-yearly siRNA alternative to PCSK9 inhibitors, has entered the market, and biosimilars of evolocumab are under FDA review. Within 12 to 24 months, the PCSK9 inhibitor market may look materially different on price. Ask your clinician whether timing your access strategy makes sense for your clinical situation.

Evidence Gaps for Women: What We Still Do Not Know

Women were underrepresented in both landmark trials discussed here. FOURIER enrolled only 25% women, meaning sex-specific event-rate data are underpowered. The LIFE trial was more balanced at 54% women, and subgroup analyses showed consistent benefit, though sex-stratified data by menopausal status were not reported.

For PCSK9 inhibitors specifically, a 2022 analysis in JAMA Cardiology examining pooled data from FOURIER and ODYSSEY OUTCOMES found that women derived similar relative risk reductions from PCSK9 inhibition as men, but had lower absolute event rates, resulting in higher numbers needed to treat. A woman with a 5-year ASCVD event risk of 8% will derive less absolute benefit from Repatha than a woman with a 20% five-year risk. This does not argue against using Repatha in high-risk women; it argues for accurate risk stratification before initiating an expensive therapy.

For losartan, real-world use in women across the reproductive lifespan is common and well-characterized pharmacologically, but clinical trial data specifically addressing perimenopausal hypertension or PCOS-related hypertension remain sparse.